Theralase Expands Intellectual Property Portfolio
Retrieved on:
Tuesday, June 28, 2022
TSX Venture Exchange, Patient, PDC, Research, TSX, Trial of the century, MAK Technologies, Inc., Non-small-cell lung carcinoma, Studie II, GLOBE, Mechanism of action, COVID-19, Cancer, Company, AES, Health Canada, Bacteria, Risk, IP, Reactive oxygen species, Technology, Singlet oxygen, Virus, Safety, Incidence, CR, TLT, Time, Intellectual property, Patent, News, Glioblastoma, Recurrence, NMIBC, Interim, Christian democracy, Pharmaceutical industry
Theralase has recently been granted a Brazilian patent for, Metal-Based Thiopene Photodynamic Compounds and their Use (Patent).
Key Points:
- Theralase has recently been granted a Brazilian patent for, Metal-Based Thiopene Photodynamic Compounds and their Use (Patent).
- The patent advances Theralases intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology (ACT) platform.
- This patent further strengthens the extensive portfolio of patents already held by Theralase.
- Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer (CEO) and Chief Scientific Officer (CSO), Theralase stated that, This patent is strategic to opening up new international opportunities for Theralase by expanding its IP portfolio of medical laser and oncology focused technologies internationally.